NCT06980207View on ClinicalTrials.gov

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Hallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of Schizophrenia

Interventions

DRUG

LY03017

administered orally

DRUG

LY03017-Placebo

administered orally

Trial Locations (1)

Unknown

Shanghai Mental Health Center, Shanghai

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY